{"result": "(\"entity\"<|>PET 18F-FDG<|>EVENT<|>PET 18F-FDG is a diagnostic imaging technique used to evaluate the response to treatment in patients with metastatic disease and to stage poorly differentiated tumors or invasive Hürthle cell carcinomas.)\n##\n(\"entity\"<|>I-131<|>EVENT<|>I-131 is a radioactive isotope used in the treatment of thyroid cancer, particularly in differentiated thyroid cancer.)\n##\n(\"entity\"<|>TIROIDES<|>GEO<|>Tiroides refers to the thyroid gland, which is involved in hormone production and is the site of various cancers, including differentiated thyroid cancer.)\n##\n(\"entity\"<|>HAUGEN BR<|>PERSON<|>Haugen BR is an author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>ALEXANDER EK<|>PERSON<|>Alexander EK is a co-author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>BIBLE KC<|>PERSON<|>Bible KC is a co-author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>DOHERTY GM<|>PERSON<|>Doherty GM is a co-author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>MANDEL SJ<|>PERSON<|>Mandel SJ is a co-author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>NIKIFOROV YE<|>PERSON<|>Nikiforov YE is a co-author of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.)\n##\n(\"entity\"<|>DEANDREIS D<|>PERSON<|>Deandreis D is a researcher who has contributed to studies on the correlation of histological patterns of metastatic thyroid cancer with patient outcomes.)\n##\n(\"entity\"<|>LEBOULLEUX S<|>PERSON<|>Leboulleux S is a researcher involved in the assessment of the incremental value of recombinant thyrotropin stimulation before PET imaging in thyroid cancer patients.)\n##\n(\"relationship\"<|>PET 18F-FDG<|>I-131<|>PET 18F-FDG is used to evaluate the response to treatment with I-131 in patients with differentiated thyroid cancer<|>8)\n##\n(\"relationship\"<|>HAUGEN BR<|>PET 18F-FDG<|>Haugen BR is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>ALEXANDER EK<|>PET 18F-FDG<|>Alexander EK is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>BIBLE KC<|>PET 18F-FDG<|>Bible KC is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>DOHERTY GM<|>PET 18F-FDG<|>Doherty GM is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>MANDEL SJ<|>PET 18F-FDG<|>Mandel SJ is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>NIKIFOROV YE<|>PET 18F-FDG<|>Nikiforov YE is one of the authors of the guidelines that discuss the use of PET 18F-FDG in the management of thyroid cancer<|>7)\n##\n(\"relationship\"<|>DEANDREIS D<|>PET 18F-FDG<|>Deandreis D has conducted research related to the use of PET 18F-FDG in assessing outcomes in thyroid cancer<|>6)\n##\n(\"relationship\"<|>LEBOULLEUX S<|>PET 18F-FDG<|>Leboulleux S has conducted research related to the use of PET 18F-FDG in assessing outcomes in thyroid cancer<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: (TG) elevados (en general > 10 ng/ml) con rastreos con I-131 negativos.\n\nIgualmente se indica que se puede considerar la utilización de la PET 18F-FDG en:\n\n1. Como parte inicial de la estadificación en tumores pobremente diferenciados o carcinomas invasivos de células de Hürthle.\n2. Como herramienta pronóstica en pacientes con enfermedad metastásica para identificar lesiones de alto riesgo de rápida progresión.\n3. Para evaluar la respuesta al tratamiento sistémico o local de enfermedad metastásica o localmente invasiva.\n\nAsí pues, tanto la opción A como la C son falsas.\n\nSin embargo, la opción B es verdadera. En efecto, la captación en una PET 18F-FDG en pacientes con carcinoma diferenciado de tiroides metastásico es un factor predictivo negativo de la respuesta al tratamiento con I-131 y un factor pronóstico independiente de supervivencia. Así, en una serie de 400 pacientes con carcinoma diferenciado de tiroides a quienes en su seguimiento se había efectuado PET 18F-FDG, únicamente la edad y una captación positiva en la PET 18F-FDG fueron predictores de supervivencia en el análisis multivariante.\n---\nTIROIDES                           3\n\nFinalmente, la última opción es falsa. La sensibilidad de la PET 18F-FDG para detectar posibles metástasis de estos tumores aumenta con el estímulo con TSH. En el estudio de Lebou-lleux et al., en el que se realizó PET 18F-FDG antes y después de un estímulo con TSHrh a 63 pacientes con cáncer diferenciado de tiroides y Tg elevadas, encontraron un total de 108 lesiones en 48 órganos en 30 de estos pacientes. La PET estimulada detectó el 95% de estas lesiones, frente al 81% de la PET basal (p = 0,001).\n\nReferencias:\n- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.\n- Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498-505.\n- Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159-69.\n- Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009;94:1310-6.\n\n## 3.7 Miscelánea\n\n45. En qué situación no está aumentada la TBG (proteína transportadora de tiroxina):\nA. Toma de estrógenos.\nB. Embarazo.\nC. Toma de andrógenos anabolizantes.\nD. Neonatos.\n\nCOMENTARIO\n\nLas hormonas tiroideas circulan en sangre unidas a una proteína trasportadora (TBG). Esta globulina es producida por el hígado y sus niveles están influidos por una serie de factores. El más importante de ellos son los estrógenos, que estimulan su síntesis por los hepatoci-tos, de forma que, en las situaciones de hiperestrogenismo, como es la toma de estrógenos o el embarazo, la TBG puede duplicar sus valores normales (opciones A y B son ciertas).\n\nEn el neonato, los valores de TBG se encuentran elevados, tanto en los nacidos a término como en los pretérmino o pequeños para su edad gestacional (opción D cierta).\n\nLa afirmación errónea es la contenida en la opción C. En efecto, los andrógenos, al contra-rio que los estrógenos, disminuyen la producción hepática de TBG, por lo que sus valores disminuyen durante la toma de andrógenos anabolizantes.\n\nReferencias:\n- Jacobsen BB, Hummer L. Changes in serum concentrations of thyroid hormones and thyroid hormone-binding proteins during early infancy. Studies in healthy fullterm, small-for-gestational age and preterm infants aged 7 to 240 days. Acta Paediatr Scand. 1979;\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}